- Home
- MGNX vs VEEA Comparison
MGNX vs VEEA Comparison
Compare MGNX & VEEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- VEEA
- Stock Information
- Founded
- MGNX 2000
- VEEA 2014
- Country
- MGNX United States
- VEEA United States
- Employees
- MGNX N/A
- VEEA N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- VEEA
- Sector
- MGNX Health Care
- VEEA
- Exchange
- MGNX Nasdaq
- VEEA NYSE
- Market Cap
- MGNX 97.2M
- VEEA 112.2M
- IPO Year
- MGNX 2013
- VEEA N/A
- Fundamental
- Price
- MGNX $1.36
- VEEA $2.01
- Analyst Decision
- MGNX Hold
- VEEA
- Analyst Count
- MGNX 9
- VEEA 0
- Target Price
- MGNX $5.33
- VEEA N/A
- AVG Volume (30 Days)
- MGNX 378.7K
- VEEA 46.3K
- Earning Date
- MGNX 05-13-2025
- VEEA 06-10-2025
- Dividend Yield
- MGNX N/A
- VEEA N/A
- EPS Growth
- MGNX N/A
- VEEA N/A
- EPS
- MGNX N/A
- VEEA N/A
- Revenue
- MGNX $154,050,000.00
- VEEA $139,252.00
- Revenue This Year
- MGNX N/A
- VEEA N/A
- Revenue Next Year
- MGNX $45.52
- VEEA N/A
- P/E Ratio
- MGNX N/A
- VEEA N/A
- Revenue Growth
- MGNX 255.31
- VEEA N/A
- 52 Week Low
- MGNX $0.99
- VEEA $1.33
- 52 Week High
- MGNX $5.77
- VEEA $18.56
- Technical
- Relative Strength Index (RSI)
- MGNX 39.88
- VEEA N/A
- Support Level
- MGNX $1.44
- VEEA N/A
- Resistance Level
- MGNX $1.58
- VEEA N/A
- Average True Range (ATR)
- MGNX 0.11
- VEEA 0.00
- MACD
- MGNX -0.02
- VEEA 0.00
- Stochastic Oscillator
- MGNX 17.65
- VEEA 0.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About VEEA VEEA INC
Veea Inc is a company providing edge platform having extensive knowledge and expertise on content delivery and edge computing, and has brought a broad range of Wi-Fi, 4G/5G mobile wireless, and IoT products to market over the past two decades. It has first-in-class VeeaHub smart computing hubs integrate a full range of connectivity options, application processing power, and a full security stack to form an elastic edge computing platform with a dynamic connectivity and application mesh that can easily be deployed and centrally managed from the cloud.